Sponsor

Queen Mary University of London

Clinical research sponsor

How to interpret these research links

Connected source records

The exact organization name Queen Mary University of London appears in 97 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Published trials97
Recruiting shown13
Roles2
SourceClinicalTrials.gov
Advertisement

Clinical trials

60 shown
Trans and Non-binary Prostate-Specific Antigen Reference Interval Determination StudyNCT06987045 · lead sponsor · 2026-04-04
RECRUITING
Population Based Germline Testing for Early Detection and Prevention of CancerNCT07498829 · lead sponsor · 2025-12-18
RECRUITING
Investigating Datopotamab Deruxtecan Plus Durvalumab Versus Datopotamab Deruxtecan in Patients With PDL1-negative Metastatic Triple-negative Breast CancerNCT06954480 · lead sponsor · 2025-10-27
RECRUITING
Children's Health, Respiratory Inflammation and Short-term Air PollutionNCT07431021 · lead sponsor · 2025-10-20
RECRUITING
The Barts Charity Children's Environmental Health ClinicNCT06447974 · lead sponsor · 2025-07-24
RECRUITING
Artificial Intelligence-Assisted Magnetic Resonance Imaging for Quality, Efficiency and Equity in the National Health Service (NHS) Care of Multiple SclerosisNCT07111637 · lead sponsor · 2025-06-14
RECRUITING
Εffectiveness of a Digital Social Intervention in Primary CareNCT06849245 · lead sponsor · 2025-02-25
RECRUITING
Cardio-Renal RegistryNCT06521801 · lead sponsor · 2024-08-01
RECRUITING
The Use of the CUE1/CUE1+ in People With Parkinson's Disease and Related DisordersNCT06174948 · lead sponsor · 2024-03-25
RECRUITING
Diagnosing Variable Primary Aldosteronism.NCT05765786 · lead sponsor · 2023-02-24
RECRUITING
Natalizumab for the Treatment of People With Inflammatory Demyelination Suggestive of Multiple Sclerosis, or Definite Multiple Sclerosis, at First Presentation (AttackMS)NCT05418010 · lead sponsor · 2022-12-01
RECRUITING
SIZOMUS Safety of Ixazomib Targeting Plasma Cells in Multiple SclerosisNCT03783416 · lead sponsor · 2020-06-15
RECRUITING
Periodontal Assessment of a Bariatric Care PopulationNCT04851470 · lead sponsor · 2014-01-31
RECRUITING
Artificial Intelligence-based Parkinson's Disease Risk Assessment (AI-PRA) StudyNCT07706829 · lead sponsor · 2026-10-01
NOT_YET_RECRUITING
Baxdrostat and Molecular Imaging of Adrenal Cytoreduction in Primary AldosteronismNCT07800858 · lead sponsor · 2026-09-15
NOT_YET_RECRUITING
Reusable Face Masks to Reduce Risk of Viral Respiratory Infections and Asthma ExacerbationsNCT06885229 · lead sponsor · 2025-03-27
WITHDRAWN
Developing a Learning Health System for Primary Care in ThailandNCT06873243 · lead sponsor · 2024-11-01
ACTIVE_NOT_RECRUITING
An Adaptive Multi-arm Trial to Improve Clinical Outcomes Among Children Recovering From Complicated SAMNCT05994742 · lead sponsor · 2024-07-15
COMPLETED
Effect of Lower Doses of Colonic Nutrient Supplementation on Appetite Hormones and Food Intake in Obese AdultsNCT07491835 · lead sponsor · 2023-10-18
COMPLETED
Colonic Delivery of DIM and Perilla Oil on Gut Hormones and Food Intake in ObesityNCT07448519 · lead sponsor · 2023-06-13
COMPLETED
Effect of a Proposed Cav1.3 Inhibitor in Primary AldosteronismNCT05686993 · lead sponsor · 2023-04-24
COMPLETED
Investigating CBF and ICP Using DCSNCT06039098 · lead sponsor · 2023-01-05
COMPLETED
Feasibility of an Asthma Online Social InterventionNCT05829265 · lead sponsor · 2022-12-09
COMPLETED
Assessing the Impact of Non-tailpipe Emissions From Traffic on the Asthmatic AirwayNCT05848791 · lead sponsor · 2022-12-01
COMPLETED
SCRATCH-HTN Study: Evaluating Autonomic Neuromodulation Using Trans-cutaneous Vagal Stimulation in Hypertensive PatientsNCT05179343 · lead sponsor · 2022-08-01
COMPLETED
Implementing Long-Acting Novel AntiretroviralsNCT05294159 · lead sponsor · 2022-07-18
COMPLETED
ADAs to AlemtuzumabNCT06310343 · lead sponsor · 2022-07-12
COMPLETED
Aspirin and Neutrophils in PreeclampsiaNCT04974892 · lead sponsor · 2022-04-27
COMPLETED
Circulating Tumour Cells as Biomarkers to Predict Prostate Cancer Metastasis for Treatment Stratification of CancerNCT05533515 · lead sponsor · 2022-02-08
COMPLETED
Bacterial Lysate In Preventing AsthmaNCT05064631 · lead sponsor · 2022-01-12
COMPLETED
ChariotMS - Cladribine to Halt Deterioration in People With Advanced Multiple SclerosisNCT04695080 · lead sponsor · 2021-06-25
ACTIVE_NOT_RECRUITING
Are Diabetics Type 2 More Prone to Dental Caries?NCT04883086 · lead sponsor · 2020-12-15
COMPLETED
Identification of Autoantigens in EGPA and Severe Eosinophilic AsthmaNCT04671446 · lead sponsor · 2020-12-10
COMPLETED
Paclitaxel Plus Pembrolizumab vs. Paclitaxel Weekly in ER+ Luminal B Metastatic Breast CancerNCT03841747 · lead sponsor · 2020-12-01
WITHDRAWN
Famciclovir in Multiple SclerosisNCT05283551 · lead sponsor · 2020-11-25
UNKNOWN
Personalised Electronic Record Supported Optimisation When Alone for Patients With HypertensionNCT04559074 · lead sponsor · 2020-10-23
COMPLETED
Personalised Electronic Record Supported Optimisation of Amlodipine for Patients With HypertensionNCT06713785 · lead sponsor · 2020-09-26
WITHDRAWN
Under and Over Rehabilitation StudyNCT04490044 · lead sponsor · 2020-09-01
COMPLETED
Cardiac and Immune Cell Function in PreeclampsiaNCT04508582 · lead sponsor · 2020-01-07
COMPLETED
AZD1656 in Transplantation With Diabetes tO PromoTe Immune TOleraNceNCT05216172 · lead sponsor · 2019-12-13
COMPLETED
Oral Cladribine B-cell StudyNCT06415864 · lead sponsor · 2019-07-01
COMPLETED
Achieving Control of Asthma in Children In AfricaNCT03990402 · lead sponsor · 2019-05-16
COMPLETED
The Effect of Food Supplements on Food Intake and Gut Hormone LevelsNCT04292236 · lead sponsor · 2019-02-22
COMPLETED
Investigate the Contribution of Ipatasertib to Neoadjuvant Chemotherapy Plus Atezolizumab in TNBCNCT05498896 · lead sponsor · 2018-12-19
ACTIVE_NOT_RECRUITING
Self-management Intervention to Improve Adolescents' Asthma ControlNCT03536416 · lead sponsor · 2018-12-18
COMPLETED
UK Registry for Baroreflex Activation TherapyNCT03730519 · lead sponsor · 2018-11-01
TERMINATED
An Imaging Study in ER Negative Breast Cancer by Targeting αvβ6NCT06978478 · lead sponsor · 2018-06-19
WITHDRAWN
Effect of Dietary Nitrate Ingestion in Heart FailureNCT03511248 · lead sponsor · 2018-06-01
TERMINATED
Study in Patients With Tumours Requiring Arginine to Assess ADI-PEG 20 With Atezolizumab, Pemetrexed and CarboplatinNCT03498222 · lead sponsor · 2018-06-01
WITHDRAWN
Pre-operative Immunotherapy Combination Strategies in Breast CancerNCT03395899 · lead sponsor · 2017-12-21
COMPLETED
Neurofilaments for NEDA Assessing in MSNCT03250169 · lead sponsor · 2017-08-01
TERMINATED
Investigation of Dietary Nitrate Effects in Hypertension-induced Target Organ DamageNCT03088514 · lead sponsor · 2017-03-23
COMPLETED
A Study to Examine the Effectiveness of Aspirin and/or Vitamin D3 to Prevent Prostate Cancer ProgressionNCT03103152 · lead sponsor · 2016-12-01
COMPLETED
Optimizing Vitamin D Status in Children With Wheeze / Asthma (OPTIVIT)NCT02880930 · lead sponsor · 2016-12-01
COMPLETED
IMaging Pilot Study of the αvβ6 Integrin Radiotracer [18F]-A20FMDV2 in PAtients With Solid Cancer TypesNCT04285996 · lead sponsor · 2016-03-17
COMPLETED
Robotic Surgery After Focal Ablation TherapyNCT03011606 · lead sponsor · 2016-02-01
COMPLETED
Short-term Preoperative Treatment With Enzalutamide, Alone or in Combination With Exemestane in Primary Breast CancerNCT02676986 · lead sponsor · 2015-08-10
COMPLETED
A Study of AZD2014 in Combination With Selumetinib in Patients With Advanced CancersNCT02583542 · lead sponsor · 2015-06-01
UNKNOWN
Th17 Responses Evaluated in RA Patients on Inhibitors of TNFαNCT02620189 · lead sponsor · 2015-03-01
COMPLETED
Protective Role of Oxcarbazepine in Multiple SclerosisNCT02104661 · lead sponsor · 2014-10-01
COMPLETED

Drugs studied in this sponsor's trials

35 mapped RxNorm concepts

These drug records are connected through ClinicalTrials.gov studies listing Queen Mary University of London as a sponsor, collaborator or responsible party. Each count is the number of distinct trials containing the mapped drug intervention. This does not establish that the organization manufactures, owns, sells or developed the drug.

Most studied mapped drug conceptsDistinct linked trials per RxNorm concept; one trial may study several drugs.
placebo8
atezolizumab3
paclitaxel3
alemtuzumab2
amlodipine2
anastrozole2
carboplatin2
amiloride1
placebo RxCUI 8375 · Lead sponsor in 6 linked trial(s) · 1 currently recruiting 8 trials atezolizumab RxCUI 1792776 · Lead sponsor in 3 linked trial(s) · 0 currently recruiting 3 trials paclitaxel RxCUI 56946 · Lead sponsor in 3 linked trial(s) · 0 currently recruiting 3 trials alemtuzumab RxCUI 117055 · Lead sponsor in 2 linked trial(s) · 0 currently recruiting 2 trials amlodipine RxCUI 17767 · Lead sponsor in 2 linked trial(s) · 0 currently recruiting 2 trials anastrozole RxCUI 84857 · Lead sponsor in 2 linked trial(s) · 0 currently recruiting 2 trials carboplatin RxCUI 40048 · Lead sponsor in 2 linked trial(s) · 0 currently recruiting 2 trials amiloride RxCUI 644 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial azithromycin RxCUI 18631 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial baxdrostat RxCUI 2743398 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial bevacizumab RxCUI 253337 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial cinnarizine RxCUI 2549 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial cobimetinib RxCUI 1722365 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial cyclophosphamide RxCUI 3002 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial doxorubicin RxCUI 3639 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial durvalumab RxCUI 1919503 · Lead sponsor in 1 linked trial(s) · 1 currently recruiting 1 trial enzalutamide RxCUI 1307298 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial everolimus RxCUI 141704 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial exemestane RxCUI 258494 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial famciclovir RxCUI 68099 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial fluoxetine RxCUI 4493 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial fulvestrant RxCUI 282357 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial gemcitabine RxCUI 12574 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial isoniazid RxCUI 6038 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial

Sponsor roles

lead sponsor75
collaborator22
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.